Stock Track | Travere Therapeutics Soars 18% Pre-Market on Stellar Q3 Results and Analyst Upgrade

Stock Track10-31

Shares of Travere Therapeutics, Inc. (NASDAQ: TVTX) are surging 18.04% in pre-market trading on Friday, building on the previous day's 16.29% gain. The significant upward movement comes in the wake of the company's outstanding third-quarter 2025 financial results and a notable analyst price target increase.

Travere's Q3 2025 performance has impressed investors, with total revenue reaching $164.9 million, including $113.2 million in U.S. net product sales. The standout performer was FILSPARI (sparsentan), which saw its U.S. net product sales skyrocket by 155% year-over-year to $90.9 million. This strong sales growth has propelled the company back to profitability, reporting a net income of $25.7 million, or $0.28 per share, a remarkable turnaround from the $54.8 million net loss in the same quarter last year.

Adding to the positive sentiment, TD Cowen has raised its price target for Travere Therapeutics from $30 to $40, reflecting growing confidence in the company's prospects. Investors are also optimistic about the potential FDA approval and commercial launch of FILSPARI for Focal Segmental Glomerulosclerosis (FSGS) in the first quarter of 2026, which could further boost the company's growth trajectory. With 731 new patient start forms for FILSPARI received during the quarter and its strengthening position as a foundational therapy for IgA Nephropathy (IgAN), Travere Therapeutics appears well-positioned for continued success in the biopharmaceutical market.

Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.

Comments

We need your insight to fill this gap

Leave a comment

{"i18n":{"language":"en_US"},"isChannel":false,"data":{"share":"https://ttm.financial/m/news/1126013499?lang=en_US&edition=fundamental","thumbnail":"","is_english":true,"pubTime":"2025-10-31 18:58","share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","id":"1126013499","market":"sg","top_or_hot":-1,"title":"Stock Track | Travere Therapeutics Soars 18% Pre-Market on Stellar Q3 Results and Analyst Upgrade","media":"Stock Track","content":"<p>Shares of Travere Therapeutics, Inc. (NASDAQ: TVTX) are surging 18.04% in pre-market trading on Friday, building on the previous day's 16.29% gain. The significant upward movement comes in the wake of the company's outstanding third-quarter 2025 financial results and a notable analyst price target increase.</p>\n\n<p>Travere's Q3 2025 performance has impressed investors, with total revenue reaching $164.9 million, including $113.2 million in U.S. net product sales. The standout performer was FILSPARI (sparsentan), which saw its U.S. net product sales skyrocket by 155% year-over-year to $90.9 million. This strong sales growth has propelled the company back to profitability, reporting a net income of $25.7 million, or $0.28 per share, a remarkable turnaround from the $54.8 million net loss in the same quarter last year.</p>\n\n<p>Adding to the positive sentiment, TD Cowen has raised its price target for Travere Therapeutics from $30 to $40, reflecting growing confidence in the company's prospects. Investors are also optimistic about the potential FDA approval and commercial launch of FILSPARI for Focal Segmental Glomerulosclerosis (FSGS) in the first quarter of 2026, which could further boost the company's growth trajectory. With 731 new patient start forms for FILSPARI received during the quarter and its strengthening position as a foundational therapy for IgA Nephropathy (IgAN), Travere Therapeutics appears well-positioned for continued success in the biopharmaceutical market.</p>","source":"ai_movement_en","html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>Stock Track | Travere Therapeutics Soars 18% Pre-Market on Stellar Q3 Results and Analyst Upgrade</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nStock Track | Travere Therapeutics Soars 18% Pre-Market on Stellar Q3 Results and Analyst Upgrade\n</h2>\n\n<h4 class=\"meta\">\n\n\n<a class=\"head\" href=\"https://laohu8.com/wemedia/1086803395\">\n\n\n<div class=\"h-thumb\" style=\"background-image:url(https://static.tigerbbs.com/a81accab1e7ee4144dc051f71903a390);background-size:cover;\"></div>\n\n<div class=\"h-content\">\n<p class=\"h-name\">Stock Track </p>\n<p class=\"h-time\">2025-10-31 18:58</p>\n</div>\n\n</a>\n\n\n</h4>\n\n</header>\n<article>\n<p>Shares of Travere Therapeutics, Inc. (NASDAQ: TVTX) are surging 18.04% in pre-market trading on Friday, building on the previous day's 16.29% gain. The significant upward movement comes in the wake of the company's outstanding third-quarter 2025 financial results and a notable analyst price target increase.</p>\n\n<p>Travere's Q3 2025 performance has impressed investors, with total revenue reaching $164.9 million, including $113.2 million in U.S. net product sales. The standout performer was FILSPARI (sparsentan), which saw its U.S. net product sales skyrocket by 155% year-over-year to $90.9 million. This strong sales growth has propelled the company back to profitability, reporting a net income of $25.7 million, or $0.28 per share, a remarkable turnaround from the $54.8 million net loss in the same quarter last year.</p>\n\n<p>Adding to the positive sentiment, TD Cowen has raised its price target for Travere Therapeutics from $30 to $40, reflecting growing confidence in the company's prospects. Investors are also optimistic about the potential FDA approval and commercial launch of FILSPARI for Focal Segmental Glomerulosclerosis (FSGS) in the first quarter of 2026, which could further boost the company's growth trajectory. With 731 new patient start forms for FILSPARI received during the quarter and its strengthening position as a foundational therapy for IgA Nephropathy (IgAN), Travere Therapeutics appears well-positioned for continued success in the biopharmaceutical market.</p>\n\n</article>\n</div>\n</body>\n</html>\n","isBrief":false,"type":0,"news_type":1,"symbol":"TVTX","symbol_name":"Travere Therapeutics, Inc.","start_time":0,"source_url":"","article_id":"1126013499","we_media_id":"1086803395","thumbnails":[],"rights":null,"url":"https://stock-news.laohu8.com/highlight/detail?id=1126013499","pubTimestamp":1761908301,"columns":[],"sourceInfo":{"source_id":"ai_movement_en","name":"Stock Track"},"weMediaInfo":{"media_name":"Stock Track","introduction":"Track stock‘s movements and relevant news","home_visible":1,"id":"1086803395","head_image":"https://static.tigerbbs.com/a81accab1e7ee4144dc051f71903a390"},"summary":"Shares of Travere Therapeutics, Inc. (NASDAQ: TVTX) are surging 18.04% in pre-market trading on Friday, building on the previous day's 16.29% gain. The significant upward movement comes in the wake...","collect":0,"end_time":0,"defaultTopTitle":"","property":[],"viewcount":null,"language":"en","relate_stocks":{"TVTX":"Travere Therapeutics, Inc."},"translate_title":"股票追踪|Travere Therapeutics因出色的第三季度业绩和分析师升级而盘前飙升18%","themeId":"","isJumpTheme":false,"ttsUrl":null,"symbols_score_info":{"TVTX":1},"content_text":"Shares of Travere Therapeutics, Inc. (NASDAQ: TVTX) are surging 18.04% in pre-market trading on Friday, building on the previous day's 16.29% gain. The significant upward movement comes in the wake of the company's outstanding third-quarter 2025 financial results and a notable analyst price target increase.\nTravere's Q3 2025 performance has impressed investors, with total revenue reaching $164.9 million, including $113.2 million in U.S. net product sales. The standout performer was FILSPARI (sparsentan), which saw its U.S. net product sales skyrocket by 155% year-over-year to $90.9 million. This strong sales growth has propelled the company back to profitability, reporting a net income of $25.7 million, or $0.28 per share, a remarkable turnaround from the $54.8 million net loss in the same quarter last year.\nAdding to the positive sentiment, TD Cowen has raised its price target for Travere Therapeutics from $30 to $40, reflecting growing confidence in the company's prospects. Investors are also optimistic about the potential FDA approval and commercial launch of FILSPARI for Focal Segmental Glomerulosclerosis (FSGS) in the first quarter of 2026, which could further boost the company's growth trajectory. With 731 new patient start forms for FILSPARI received during the quarter and its strengthening position as a foundational therapy for IgA Nephropathy (IgAN), Travere Therapeutics appears well-positioned for continued success in the biopharmaceutical market.","kind":"news","is_publish_news":true,"is_publish_highlight":false,"is_publish_live":false,"is_publish_wemedia":null,"editions":null,"column":"","sentiment":"2","news_tag":"movement","news_rank":0,"symbols":[],"gpt_button":0,"need_auth":false,"code":"91000000","status":"200"},"commentList":[],"isCommentEnd":true,"newsSizeData":{"likeSize":0,"commentSize":0,"repostSize":0,"favoriteSize":0,"likeStatus":false,"favoriteStatus":false},"APP":{"userAgent":"Mozilla/5.0 AppleWebKit/537.36 (KHTML, like Gecko; compatible; ClaudeBot/1.0; +claudebot@anthropic.com)","isDev":false,"isTTM":true,"deviceId":"web-server-community-laohu8-v3","version":"4.35.10","shortVersion":"4.35.10","platform":"web","vendor":"web","appName":"ttm","isIOS":false,"isAndroid":false,"isTiger":false,"isTHS":false,"isWeiXin":false,"isWeiXinMini":false,"isWeiBo":false,"isQQ":false,"isBaiduSwan":false,"isBaiduBox":false,"isDingTalk":false,"isToutiao":false,"isOnePlus":false,"isHuaWei":false,"isXiaomi":false,"isXiaomiWebView":false,"isOppo":false,"isVivo":false,"isSamsung":false,"isMobile":false},"href":"/m/news/1126013499","isCrawlerRequest":true}